Deng Chao, Deng Bo, Jia Liqun, Tan Huangying
Beijing University of Chinese Medicine, Beijing, China.
Department of Medical Oncology, Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
BMJ Open. 2017 Jun 21;7(6):e014916. doi: 10.1136/bmjopen-2016-014916.
Diarrhoea is a common adverse effect induced by chemotherapy that can reduce the dose of chemotherapeutic drugs or interrupt the chemotherapy schedule. The current treatment strategies have various limitations. It has been shown that long-acting release octreotide (octreotide LAR) can decrease the occurrence and severity of diarrhoea, yet the efficacy of octreotide LAR in preventing chemotherapy-induced diarrhoea (CID) remains to be assessed. The main objective of this paper was to draw up a protocol for systematic review to evaluate the protective effects of octreotide LAR on CID.
We searched Medline, EMBASE, the Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Data and the VIP Database without language restrictions from inception until 1 September 2016. The references of relevant studies were also manually searched. Two investigators independently accessed the selected studies, extracted data and assessed the reliability of the studies. Any discrepancies were resolved by a third investigator. The effect size of the selected studies was assessed by different measures based on the type of data. The selected studies were descriptively analysed. We then chose a fixed-effect model or a random-effect model based on statistical homogeneity, and pooled data from the studies for meta-analysis, if possible. The primary outcome was the incidence of diarrhoea. The secondary outcomes were the duration of diarrhoea, incidence of diarrhoea-associated symptoms, physical function and quality of life. All statistical analyses were performed by Review Manager V.5.3.
This systematic review did not require ethics approval, because it included aggregated published data, and not individual patient data. The review was published in a peer-reviewed journal.
This systematic review protocol was registered with PROSPERO (registration number: CRD 42016048573).
腹泻是化疗引起的常见不良反应，可导致化疗药物剂量减少或化疗疗程中断。目前的治疗策略存在各种局限性。已表明长效释放奥曲肽（奥曲肽LAR）可降低腹泻的发生率和严重程度，但奥曲肽LAR预防化疗引起的腹泻（CID）的疗效仍有待评估。本文的主要目的是制定一项系统评价方案，以评估奥曲肽LAR对CID的保护作用。
我们检索了Medline、EMBASE、Cochrane图书馆、中国知网、万方数据和维普数据库，检索时间从建库至2016年9月1日，无语言限制。还手动检索了相关研究的参考文献。两名研究者独立查阅选定的研究，提取数据并评估研究的可靠性。任何分歧由第三名研究者解决。根据数据类型，通过不同方法评估选定研究的效应量。对选定的研究进行描述性分析。然后根据统计同质性选择固定效应模型或随机效应模型，如有可能，汇总研究数据进行荟萃分析。主要结局是腹泻的发生率。次要结局是腹泻持续时间、腹泻相关症状的发生率、身体功能和生活质量。所有统计分析均使用Review Manager V.5.3进行。
本系统评价不需要伦理批准，因为它纳入的是已发表数据的汇总，而非个体患者数据。该评价发表在同行评审期刊上。
本系统评价方案已在国际前瞻性系统评价注册库（PROSPERO）注册（注册号：CRD 42016048573）。
